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prototype of the DA provides clear information about the 
treatment options and their side-effects. Issues about the 
usability of the DA were reported and enabled us to improve 
and simplify the DA. The next step is to perform a study to 
establish the impact of the DA on the decisional conflict and 
the shared decision making process.  
 
Conclusion: The systematic and iterative approach used to 
develop and validate the DA, allows to follow a thoroughly 
development process, and to gain knowledge about decisional 
needs.  
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Purpose or Objective: Van Werkhoven et al. developed a 
nomogram to predict the 10-years ipsilateral breast relapse 
(IBR) after breast conserving therapy (BCT) for breast cancer 
(BC) based on the European Organisation for Research and 
Treatment of Cancer (EORTC) ‘boost no boost’-trial with a 
concordance probability estimate (CPE) of 0.68 (van 
Werkhoven E, et al. 2011, Radiother Oncol). The nomogram 
includes histologic grade, ductal carcinoma in situ (DCIS), 
tumour diameter, age, tamoxifen, chemotherapy and boost. 
The aim of this study was to evaluate the performance of 
that algorithm in an independent cohort. 
 
Material and Methods: We retrospectively identified 1866 BC 
patients who underwent BCT with radiotherapy from 2000 to 
2007.  
Two definitions of IBR were considered where simultaneous 
regional or distant recurrence were either censored (conform 
EORTC analysis) or included as event.  
Patient, tumour and treatment characteristics were 
evaluated in uni- and multivariable analysis.  
Firstly we assessed discrimination, i.e. the extent to which 
patients predicted to be at higher risk exhibit higher event 
rates than those deemed at lower risk, by the CPE. The CPE 
was determined based on a Cox model with time to IBR as 
outcome and the EORTC nomogram 10-years IBR-free 
probability as the only covariate. Secondly a calibration plot 
was drawn, showing the predicted 10-years IBR-free 
probabilities against observed Kaplan–Meier estimates, to 
reflect prediction accuracy, i.e. the absence of over- or 
underestimation. 
 
Results: Median follow-up time was 10.75 years.  
Patients were on average older (58 vs 54 years), had a larger 
average tumour diameter (18 mm vs 15 mm) and were more 
likely to have received chemotherapy (29.7 % vs 15.7 %), to 
have a high grade disease (37.0 % vs 23.5 %) and to have a 
DCIS (69.8 % vs 57.8 %). Twenty-three percent of the patients 
received tamoxifen in the EORTC group, whereas 81.6 % 
received hormonal therapy in the validation group. Almost all 
patients (99.7 %) in the validation group received a boost 
versus 50.4 % in the EORTC cohort. Noteworthy on the 
variables not included in the nomogram, patients in the 
validation cohort had a higher percentage of oestrogen and 
progesterone receptor positivity (86.4 % vs 71.7 % and 75.9 % 
vs 64.3 %, respectively) and 10.2 % had HER2 overexpression. 
The 10-years IBR-rate was 1.4 %. On multivariable analysis, 
only the omission of the boost dose was a significant 
prognosticator of IBR (p < 0.01) with a trend for age (p = 
0.06).  
The nomogram demonstrated suboptimal discrimination, with 
a CPE of 0.54, and suboptimal calibration with an 
overestimation of the IBR-risk in general (Table 1 – Figure 1). 
 
 
 
 
Conclusion: The EORTC predictive model for IBR in BC 
patients lacks accuracy in this more recent study population. 
Therefore the model should be tested and verified in 
additional, large patient populations and incorporating 
molecular subtyping might be needed. 
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Purpose or Objective: To evaluate acute toxicity and early 
clinical outcomes of hypofractionated simultaneous 
integrated boost (SIB) approach with Volumetric Modulated 
Arc Therapy (VMAT) as adjuvant treatment after breast-
conserving surgery. 
 
Material and Methods: Patients presenting early-stage breast 
cancer were enrolled in a phase II trial. Eligibility criteria 
were as follow: age >18  years, invasive cancer or DCIS, Stage 
I to II (T <3 cm and N ≤ 3), breast -conserving surgery, any 
systemic therapy was allowed in neoadjuvant or adjuvant 
setting. All patients underwent VMAT-SIB technique to 
irradiate the whole breast with concomitant boost irradiation 
of the tumor bed. Doses to whole breast and surgical bed 
were 40.5 Gy and 48 Gy respectively, delivered in 15 
fractions over 3 weeks Acute skin toxicities were recorded 
according to RTOG scoring criteria, and late skin toxicities 
according to CTCAE v4.0. Cosmetic outcomes were assessed 
as excellent/good or fair/poor according to the Harvard 
scale. 
 
Results: Between August 2010 and January 2015, 840 
consecutive patients were treated. Median age was 60 year 
(range 19-89 years). The median follow up was 16 months 
(range 6-55). At the end of RT treatment skin toxicity profile 
was G1 in 49% of the patients, G2 in 13%, and one patients 
presented G3 toxicity (0.1%). At six months of follow up skin 
toxicity was G1 in 27% of patients, G2 in 1%, no G3 cases; 
